These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 39197358)

  • 1. Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK-positive advanced non-small cell lung cancer.
    Bauman JR; Liu G; Preeshagul I; Liu SV; Melosky B; Abrahami D; Li B; Thomaidou D; Duncan K; Krulewicz S; Rupp M; Lin JJ
    Lung Cancer; 2024 Sep; 195():107919. PubMed ID: 39197358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment Sequencing in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer in Japan: A Real-World Observational Study.
    Goto Y; Yamamoto N; Masters ET; Kikkawa H; Mardekian J; Wiltshire R; Togo K; Ohe Y
    Adv Ther; 2020 Jul; 37(7):3311-3323. PubMed ID: 32472430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Treatment Patterns and Outcomes Across Three Lines of Therapy in Patients with ALK+ NSCLC.
    Arnaoutakis K; Wan Y; Elliott J; Young M; Yin Y; Leventakos K; Lin HM; Dimou A
    Adv Ther; 2024 Aug; 41(8):3217-3231. PubMed ID: 38916812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ALTA-2: Phase II study of brigatinib in patients with ALK-positive, advanced non-small-cell lung cancer who progressed on alectinib or ceritinib.
    Kim ES; Barlesi F; Mok T; Ahn MJ; Shen J; Zhang P; Ou SI
    Future Oncol; 2021 May; 17(14):1709-1719. PubMed ID: 33569983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world treatment duration in ALK-positive non-small-cell lung cancer patients receiving brigatinib through the early access program.
    Lin HM; Pan X; Hou P; Allen S; Baumann P; Hochmair MJ
    Future Oncol; 2020 May; 16(15):1031-1041. PubMed ID: 32338548
    [No Abstract]   [Full Text] [Related]  

  • 6. Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing.
    Lin YT; Chiang CL; Hung JY; Lee MH; Su WC; Wu SY; Wei YF; Lee KY; Tseng YH; Su J; Chung HP; Lin CB; Ku WH; Chiang TS; Chiu CH; Shih JY
    Eur J Cancer; 2021 Oct; 156():1-11. PubMed ID: 34392186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-World Efficacy and Tolerability of Brigatinib in Patients with Non-Small Cell Lung Cancer with Prior ALK-TKIs in the United States.
    Jahanzeb M; Lin HM; Wu Y; Zhang P; Gorritz M; McGuiness CB; Huang WT; Sun K; Chen CC; Camidge DR
    Oncologist; 2022 Sep; 27(9):790-798. PubMed ID: 35781589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study).
    Descourt R; Perol M; Rousseau-Bussac G; Planchard D; Mennecier B; Wislez M; Cortot A; Guisier F; Galland L; Dô P; Schott R; Dansin E; Arrondeau J; Auliac JB; Chouaid C
    Lung Cancer; 2019 Oct; 136():109-114. PubMed ID: 31491676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world evidence of brigatinib as second-line treatment after crizotinib for ALK+ non-small cell lung cancer using South Korean claims data (K-AREAL).
    Lee JE; Nam JH; Kwon SH; Kim BK; Ha SM
    Cancer Med; 2024 Jul; 13(14):e70030. PubMed ID: 39030811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-World Treatment Patterns and Progression-Free Survival Associated with Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitor Therapies for ALK+ Non-Small Cell Lung Cancer.
    Jahanzeb M; Lin HM; Pan X; Yin Y; Wu Y; Nordstrom B; Socinski MA
    Oncologist; 2020 Oct; 25(10):867-877. PubMed ID: 32490560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Observational Study of Treatment Patterns in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer After First-Line EGFR-Tyrosine Kinase Inhibitors.
    Nadler E; Pavilack M; Espirito JL; Clark J; Fernandes A
    Adv Ther; 2020 Feb; 37(2):946-954. PubMed ID: 31955357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mixed responses to first-line alectinib in non-small cell lung cancer patients with rare ALK gene fusions: A case series and literature review.
    Li M; An Z; Tang Q; Ma Y; Yan J; Chen S; Wang Y
    J Cell Mol Med; 2021 Oct; 25(19):9476-9481. PubMed ID: 34541785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tyrosine Kinase Inhibitors With and Without Up-Front Stereotactic Radiosurgery for Brain Metastases From
    Pike LRG; Miao E; Boe LA; Patil T; Imber BS; Myall NJ; Pollom EL; Hui C; Qu V; Langston J; Chiang V; Grant M; Goldberg SB; Palmer JD; Prasad RN; Wang TJC; Lee A; Shu CA; Chen LN; Thomas NJ; Braunstein SE; Kavanagh BD; Camidge DR; Rusthoven CG
    J Clin Oncol; 2024 Oct; 42(30):3606-3617. PubMed ID: 39047224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overall survival indirect treatment comparison between brigatinib and alectinib for the treatment of front-line anaplastic lymphoma kinase-positive non-small cell lung cancer using data from ALEX and final results from ALTA-1L.
    Reckamp KL; Lin HM; Cranmer H; Wu Y; Zhang P; Kay S; Walton LJ; Shen J; Popat S; Camidge DR
    Curr Med Res Opin; 2022 Sep; 38(9):1587-1593. PubMed ID: 35815801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of Central Nervous System Metastases in Patients With Advanced Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer During Crizotinib Treatment.
    Zhao Y; Zhang B; Wang S; Qiao R; Xu J; Zhang L; Zhang Y; Han B
    Clin Lung Cancer; 2019 Nov; 20(6):e631-e637. PubMed ID: 31362880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world outcomes, treatment patterns and T790M testing rates in non-small cell lung cancer patients treated with first-line first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors from the Slovenian cohort of the REFLECT study.
    Turnsek N; Devjak R; Edelbaher N; Osrajnik I; Unk M; Vidovic D; Jeric T; Janzic U
    Radiol Oncol; 2022 Aug; 56(3):371-379. PubMed ID: 35853681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Indirect comparisons of brigatinib and alectinib for front-line
    Reckamp KL; Lin HM; Cranmer H; Wu Y; Zhang P; Walton LJ; Kay S; Cichewicz A; Neupane B; Fahrbach K; Popat S; Camidge DR
    Future Oncol; 2022 Jun; 18(20):2499-2510. PubMed ID: 35608148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progression patterns, resistant mechanisms and subsequent therapy for ALK-positive NSCLC in the era of second-generation ALK-TKIs.
    Wu L; Zou Z; Li Y; Hao X; Ying J; Li J; Xing P
    J Transl Med; 2024 Jun; 22(1):585. PubMed ID: 38902768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted therapy for advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer.
    Cameron LB; Hitchen N; Chandran E; Morris T; Manser R; Solomon BJ; Jordan V
    Cochrane Database Syst Rev; 2022 Jan; 1(1):CD013453. PubMed ID: 34994987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brigatinib vs alectinib in crizotinib-resistant advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALTA-3).
    Popat S; Liu G; Lu S; Song G; Ma X; Yang JC
    Future Oncol; 2021 Nov; 17(32):4237-4247. PubMed ID: 34423676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.